Login / Signup

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Astrid L VoskampSugandhika KhosaTracy PhanHannah A DeBergJudy BinghamMark HewWilliam B SmithJodie AbramovitchJennifer M RollandMatthew MoyleKari Christine NadeauGideon LackMark LarchéErik R WambreRobyn Elizabeth O'HehirPascal L C HickeySara R Prickett
Published in: Allergy (2023)
This study supports the concept that PVX108 could provide a safe alternative to whole peanut immunotherapies and provides evidence of durable peanut-specific T-cell modulation. Translation of these findings to clinical efficacy in ongoing Phase 2 trials would provide important proof-of-concept for using peptides to treat food allergy.
Keyphrases
  • amino acid